Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017 5 Biotechs the Super-Rich Are Favoring in 2017 (So Far) March 21, 2017 Oxitec's Friendly Aedes Mosquito Receives Positive Evaluation For European Standard In Relation To Human Health And The Environment July 5, 2017
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017
Oxitec's Friendly Aedes Mosquito Receives Positive Evaluation For European Standard In Relation To Human Health And The Environment July 5, 2017
